Treatment efficacy and prognostic factors for huge HCC based on Barcelona Clinic Liver Cancer staging.
OBJECTIVE
To explore the most appropriate treatment for patients with hepatocellular cancer (HCC)>10 cm by using the Barcelona Clinic Liver Cancer (BCLC) classification.


METHODS
A total of 124 HCC patients undergoing surgery were selected. Disease-free survival (DFS), overall survival (OS) and prognostic factors were respectively assessed.


RESULTS
This study showed that the cumulative 1-, 3-, 5-year survival rates were 79.7%, 59.8% and 41.6% in BCLC-A patients, 76.2%, 9.5% and 0% in BCLC-B patients and 44.9%, 0% and 0% in BCLC-C patients, respectively. The 1-, 3-, 5-year DFS rates were 49%, 24.5% and 9.1% in BCLC-A patients, 7.5%, 0% and 0% in BCLC-B patients, respectively. No BCLC-C patients survived 1 year after surgery. Multivariate analysis indicated that hepatitis B surface antigen (HBsAg), vascular invasion, intra-hepatic metastasis, curative resection, tumor rupture and pathologic differentiation were independent prognostic factors.


CONCLUSIONS
Surgery is effective and safe for patients with HCC>10 cm with sufficient hepatic reserve.
Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China E-mail : ljyljy99@aliyuan.com.
Zhi-Ming
ZM
Zhang
Yu-Mei
YM
Zhang
Sheng
S
Gao
Wei-Ping
WP
Yuan
Yin-Nong
YN
Zhao
Bang-De
BD
Xiang
Fei-Xiang
FX
Wu
Guo-Bin
GB
Wu
Jian-Yong
JY
Liu
D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging / Q000592:standards*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult